Methods of formulating and designing liquid drug suspensions containing ion exchange resin particles
The invention relates to the formulation and quality control of liquid drug suspensions. In particular, the invention relates to methods of formulating liquid suspensions comprising drug-containing resin particles. The invention also relates to methods of confirming the acceptability of drug-containing resin particles for use in formulating liquid drug suspensions. The invention further relates to methods of formulating liquid suspensions in which drug-containing resin particles, the liquid suspension, or both are modified to achieve a desired in vitro dissolution profile. The invention also relates to a novel dissolution method and methods of predicting in vivo bioequivalence based on in vitro dissolution methods.
1. A test method comprising
(a) obtaining drug-resin complex particles;
(b) combining said drug-resin complex particles with a plurality of excipients in a liquid carrier to form a liquid test drug suspension;
(c) performing an in vitro dissolution assay to generate a test in vitro dissolution profile for the test drug suspension; and
(d) comparing said test in vitro dissolution profile to a control in vitro dissolution profile generated by an in vitro dissolution assay for a control drug suspension, to determine whether the test in vitro dissolution profile matches the control in vitro dissolution profile,
wherein said dissolution profiles are obtained prior to either suspension becoming stable to time-dependent changes to its release profile,
wherein said test drug suspension and said control drug suspension are substantially similar in physicochemical characteristics to a finally formulated suspension which is stable to time-dependent changes to its release profile, and
further wherein said control in vitro dissolution profile correlates to a target in vivo profile of a controlled release liquid suspension drug product.
2. A method for determining the acceptability of drug-resin complex particles for use in a controlled release liquid suspension drug suspension product, comprising
(a) obtaining a sample of said drug-resin complex particles;
(b) combining said sample with a plurality of excipients in a liquid carrier to form a liquid test drug suspension;
(c) performing an in vitro dissolution assay to generate a test in vitro dissolution profile for the test drug suspension;
(d) comparing said test in vitro dissolution profile to a control in vitro dissolution profile generated by an in vitro dissolution assay for a control drug suspension, to determine whether the test in vitro dissolution profile matches the control in vitro dissolution profile;
(e) accepting or rejecting said quantity of drug-resin complex particles based on the comparison of step (d),
wherein said dissolution profiles are obtained prior to either suspension becoming stable to time-dependent changes to its release profile,
wherein said test drug suspension and said control drug suspension are substantially similar in physicochemical characteristics to a finally formulated suspension which is stable to time-dependent changes to its release profile, and
further wherein said control in vitro dissolution profile correlates to a target in vivo profile of a controlled release liquid suspension drug product.
3. The method of claim 1 , wherein if the test in vitro dissolution profile does not match the control in vitro dissolution profile, further comprising modifying the drug-resin complex particles to form modified drug-resin complex particles and repeating steps (b)-(d) with said modified drug-resin complex particles.
4. The method of claim 1 , wherein if the test in vitro dissolution profile does not match the control in vitro dissolution profile, further comprising modifying the test drug suspension to form a modified test drug suspension and repeating steps (c)-(d) with said modified test drug suspension.
5. The method of claim 1 , wherein said drug-resin complex particles comprise a first plurality of particles comprising a first drug and a second plurality of particles comprising a second drug.
6. The method of claim 5 , wherein said first plurality of particles further comprises a water-permeable coating.
7. The method of claim 5 , wherein said second plurality of particles does not further comprise a water-permeable coating.
8. The method of claim 6 , wherein the water-permeable coating is an ethylcellulose coating.
9. The method of claim 5 , wherein the first drug is hydrocodone and the second drug is chlorpheniramine.
10. The method of claim 3 , wherein said drug-resin complex particles contain a water-permeable coating and said modifying comprises increasing the weight of said coating to decrease the rate of dissolution of the test suspension.
11. The method of claim 3 , wherein modifying comprises modifying the size of the drug-resin complex particle.
12. The method of claim 3 , wherein said modifying comprises increasing the amount of drug loaded above the holding capacity on said drug-resin complex particle to increase the rate of dissolution of the test suspension.
13. The method of claim 3 , wherein said modifying comprises decreasing the amount of drug loaded below holding capacity on said drug-resin complex particle to increase the rate of dissolution of the test suspension.
14. The method of claim 4 , wherein said modifying comprises altering the ionic strength of said test drug suspension.
15. The method of claim 4 , wherein said modifying comprises altering the active resin-site balance of said test drug suspension.
16. The method of claim 15 , wherein said modifying comprises adding a pre-determined amount of coated free resin.
17. The method of claim 15 , wherein said modifying comprises adding a pre-determined amount of uncoated free resin.
18. The method of claim 15 , wherein said modifying comprises by adding a pre-determined amount of free drug.
19. The method of claim 1 , wherein there is a pre-determined hold period between the formation of said test drug suspension and initiation of said dissolution assay for said test drug suspension, and there is a pre-determined hold period between the formation of said control drug suspension and initiation of said dissolution assay for said control drug suspension,
wherein the pre-determined hold period between the formation of said test drug suspension and initiation of said dissolution assay for said test drug suspension, and the pre-determined hold period between the formation of said control drug suspension and initiation of said dissolution assay for said control drug suspension are substantially identical and are substantially less than a period necessary for each drug suspension to become stable to time-dependent changes in its release profile.
20. The method of claim 19 , wherein said pre-determined hold period is less than one week.
21. The method of claim 2 , wherein there is a pre-determined hold period between the formation of said test drug suspension and initiation of said dissolution assay for said test drug suspension, and there is a pre-determined hold period between the formation of said control drug suspension and initiation of said dissolution assay for said control drug suspension,
wherein the pre-determined hold period between the formation of said test drug suspension and initiation of said dissolution assay for said test drug suspension, and the pre-determined hold period between the formation of said control drug suspension and initiation of said dissolution assay for said control drug suspension are substantially identical and are substantially less than a period necessary for each drug suspension to become stable to time-dependent changes to its release profile.
22. The method of claim 21 , wherein said pre-determined hold period is less than one week.
23. The method of claim 1 , wherein said dissolution medium initially has a pH of less than 2.0, and then is adjusted to a pH of above 6.0 about two hours after the introduction of said aliquot.